Literature DB >> 19856480

Prevalence of different HPV types and estimation of prognostic risk factors based on the linear array HPV genotyping test.

Eleni Papachristou1, Vana Sypsa, Dimitrios Paraskevis, Athanasios Gkekas, Ekaterini Politi, Electra Nicolaidou, Ioannis Anifantis, Mina Psichogiou, Artemis Tsitsika, Maria Hadjivassiliou, Georgios Petrikkos, Andreas Katsambas, Georgios Creatsas, Angelos Hatzakis.   

Abstract

The aim of the study was to evaluate the prevalence and risk factors of HPV in a gynecologic population attending outpatient clinics using two new molecular tests. The Amplicor HPV test and the Linear Array (LA) HPV Genotyping test were used for the detection of HPV DNA in 320 women. Multiple logistic regression was used to identify independent prognostic factors of HPV positivity. The agreement between the two methods in terms of their qualitative results was 89.3% (kappa: 0.63). Based on the LA results, the overall prevalence of HPV DNA was 49.1%, 95% confidence interval (95% CI: 43.5%, 54.7%). The prevalence of high-risk HPV types was 30.3%. The predominant types were HPV-6 (24.8%) and HPV-16 (20.4%). Among women with normal cytology, the prevalence of HPV was much higher in those presenting other findings, such as inflammation, than those without other abnormal findings (49.5% vs. 31.5%). On the basis of multivariate analysis, the risk of HPV infection was higher among women with multiple sexual partners [>3 vs. 1: OR = 3.1, 95% CI: (1.5, 7.2)], Pap smear findings [low/high-grade lesions vs. negative: OR = 2.8, 95% CI: (1.2, 6.5)], the presence of warts [yes vs. no: OR = 3.0, 95% CI: (1.5, 6.3)] and no history of child birth [no vs. yes: OR = 2.6, 95% CI: (1.0, 6.7)]. Younger age was an additional risk factor for HPV infection with carcinogenic genotypes [OR for 1 year increase = 0.93, 95% CI: (0.89, 0.98)]. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19856480     DOI: 10.1002/jmv.21639

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  The Prevalence of Human Papilloma Virus (HPV) in Women using Liquid Base Pap Smear in Rasht, Northern of Iran.

Authors:  Seyed Mohamad Mohseni Mehran; Mandana Mansour Ghanaei; Ali Mojtehadi
Journal:  J Clin Diagn Res       Date:  2015-07-01

Review 2.  Human papillomavirus infection by anatomical site among Greek men and women: a systematic review.

Authors:  Savas Tsikis; Lea Hoefer; Angella Charnot-Katsikas; John A Schneider
Journal:  Eur J Cancer Prev       Date:  2016-11       Impact factor: 2.497

3.  Performance evaluation of manual and automated (MagNA pure) nucleic acid isolation in HPV detection and genotyping using Roche Linear Array HPV Test.

Authors:  Aikaterini Chranioti; Evangelia Aga; Niki Margari; Christine Kottaridi; Asimakis Pappas; Ioannis Panayiotides; Petros Karakitsos
Journal:  Infect Dis Obstet Gynecol       Date:  2011-07-09

4.  Human papillomavirus genotype distribution in Madrid and correlation with cytological data.

Authors:  Paloma Martín; Linah Kilany; Diego García; Ana M López-García; Ma José Martín-Azaña; Victor Abraira; Carmen Bellas
Journal:  BMC Infect Dis       Date:  2011-11-15       Impact factor: 3.090

5.  A cross sectional study of HPV type prevalence according to age and cytology.

Authors:  Elena Argyri; Stefanos Papaspyridakos; Elpida Tsimplaki; Lina Michala; Evangelia Myriokefalitaki; Issidora Papassideri; Dimitra Daskalopoulou; Ioanna Tsiaoussi; George Magiakos; Efstathia Panotopoulou
Journal:  BMC Infect Dis       Date:  2013-01-30       Impact factor: 3.090

6.  Prevalence of human papilloma virus (HPV) and its genotypes in cervical specimens of Egyptian women by linear array HPV genotyping test.

Authors:  Mohamed A Youssef; Lobna Abdelsalam; Reem Abdelhameed Harfoush; Iman Mamdouh Talaat; Eman Elkattan; Abeer Mohey; Rana M A Abdella; Marwa Salah Farhan; Hany Ahmed Foad; Abeer Mostafa Elsayed; Naglaa A Elkinaai; Doaa Ghaith; Mohamed Elsayed Rashed; Mohamed Abd-El Ghafar; Yasser Khamis; Ahmed N Hosni
Journal:  Infect Agent Cancer       Date:  2016-02-17       Impact factor: 2.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.